John L. McGuire

Director, Clinical and Regulatory Affairs at Alcyone Therapeutics

John L. McGuire has over 12 years of professional experience in the medical and pharmaceutical fields. From 2006 to 2008, they worked as a Clinical Research Associate II at Covidien (Medtronic Minimally Invasive Therapies Group). From 2008 to 2012, they were a Clinical Operations Manager at Intrinsic Therapeutics, Inc. From 2012 to 2014, they were a Clinical Project Manager at Medtronic, and from 2014 to 2015 they were a Clinical Research Manager (Consultant) at Instrumentation Laboratory. From 2015 to 2017, they were a Global (Principal) Clinical Trial Manager at Medtronic and a Fellow at the UMass Institute for Applied Life Sciences. Since 2017, they have been a Sr. Consultant at RQMIS Inc., a Director of Clinical and Regulatory Affairs and an Associate Director of Clinical Operations at Anuncia Inc., and a Director of Clinical and Regulatory Affairs and an Associate Director of Clinical Operations at Alcyone Therapeutics.

John L. McGuire has a diverse educational background. John L. received a Master of Business Administration (MBA) in Marketing and Entrepreneurship from Isenberg School of Management, UMass Amherst. John L. also holds a Bachelor's Degree in Business Administration from the same institution. Additionally, they completed Pre-Medical Studies (Post-Baccalaureate) at University of Massachusetts Amherst. John L. also holds certifications from the Association of Clinical Research Professionals, including a CCRA (2008), ACRP-MDP (Medical Device Professional), and ACRP-PM (Certified Project Manager).

Location

Boston, United States

Links

Previous companies


Org chart

No direct reports

Teams


Offices


Alcyone Therapeutics

Alcyone Therapeutics is a biotechnology company pioneering next-generation precision central nervous system (CNS) therapies to improve the lives of patients and families impacted by severe neurological conditions. Alcyone Therapeutics is advancing a pipeline of adeno-associated virus (AAV) gene therapy programs that leverage its proprietary, next-generation CNS delivery technology platform. Alcyone Therapeutics’ lead programs target the treatment of Rett syndrome and spinal muscular atrophy with respiratory distress type 1 (SMARD1).


Industries

Employees

11-50

Links